Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072357 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
A Phase 1 study of Corneal Neovascularization and Corneal Graft Failure, sponsored by Reza Dana, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01072357: Completed Phase 1 study of Corneal Neovascularization and Corneal Graft Failure, sponsored by Reza Dana, MD.
NCT01072357 is a Phase 1 study of Corneal Neovascularization and Corneal Graft Failure that has completed, run by Reza Dana, MD. The registered enrollment target is 30 participants, below the 72-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01072357, a Phase 1 study of Corneal Neovascularization and Corneal Graft Failure, has completed, sponsored by Reza Dana, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we would like to test the safety and efficacy of local VEGF blockade in the promotion of graft survival in high risk corneal transplants.
Primary Outcome
Time from surgery to overall graft failure (regardless of cause). Graft failure was monitored throughout the entire study, but only the time points at which graft failure occurred are reported below.
Conditions Studied
Interventions
- DRUG Avastin® (bevacizumab)
- DRUG 0.9% NaCl & Refresh Liquigel
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
What the finished NCT01072357 record still lists
NCT01072357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 72-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Corneal Neovascularization appearing as the primary indexed condition, and to 2 interventions - of which Avastin® (bevacizumab) is the first listed.
NCT01072357 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01072357 about?
NCT01072357 is a clinical study titled "Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival". The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we would like to test the safety and efficacy of local VEGF blockade in t...
What is the current status of trial NCT01072357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-12. Estimated completion is 2015-01.
What conditions does trial NCT01072357 study?
This clinical trial studies the following conditions: Corneal Neovascularization, Corneal Graft Failure.
What interventions are being tested in trial NCT01072357?
The interventions under investigation include: Avastin® (bevacizumab) (DRUG), 0.9% NaCl & Refresh Liquigel (DRUG).
Who is sponsoring clinical trial NCT01072357?
This trial is sponsored by Reza Dana, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01072357 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Neovascularization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
COMPLETED · Phase 1
-
Corneal Crosslinking for Treatment of Corneal Neovascularization
RECRUITING · Phase 2
-
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia